All lobbying filings

DLA PIPER LLP (US)

DLA PIPER LLP (US) filed a Q1 termination report for INDIVIOR INC. on April 16, 2026, reporting $20,000 in lobbying income.

Lobbying for INDIVIOR INC. · Pharmaceutical company

All filings by DLA PIPER LLP (US) · Everything INDIVIOR INC. has reported

Filing · LD-2 quarterly report Q1 termination

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 16, 2026

Income

$20,000

What the client paid this registrant for the period.

Client based in

Virginia

Representation ended

Feb 4, 2026

The registrant reported terminating its work for this client.

Official filing document

Government bodies contacted 1

SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Medicare/Medicaid

H.R. 2586, Reentry Act of 2025, policies related to reimbursement of substance use disorder treatment.

Health Issues

General education on issues related to the Drug Enforcement Agency (DEA). Issues related to substance use addiction and treatment, including NIH/HHS funding levels.Issues related to access to addiction treatments, including telehealth.

Bills named in this filing 1

H.R. 2586
Reentry Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.